Page 186 - 2020_11-Haematologica-web

2674
Letters to the Editor
4Department of Hematology, Arcispedale S. Maria Nuova, Reggio Emilia; 5Division of Hematology, A.O.U. Città della Salute e della ScienzadiTorinoandDepartmentofMolecularBiotechnologyand Health Sciences, University of Torino, Torino; 6SC Ematologia, Azienda Sanitaria Universitaria Integrata, Trieste; 7Ematologia e Centro Trapianti, IRCCS Ospedale Policlinico San Martino, Genova; 8Cattedra di Ematologia, CTMO University, Parma; 9Department of Onco-Hematology, University of Perugia, Santa Maria Hospital, Terni; 10Department of Hematology, Niguarda Ca Granda Hospital, Milan; 11Department of Hematology, Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico of Milan, Milan; 12Department of Hematology, SS. Antonio e Biagio e Cesare Arrigo Hospital, Alessandria; 13Hematology, Department of Medical Science Surgery and Neurosciences, University of Siena, Siena; 14Department of Hematology, S. Camillo Hospital, Rome; 15Hematology, Department of Biomedicine and Prevention, University Tor Vergata, Rome; 16Department of Hematology, University of Messina, Messina; 17Emergency and Transplantation Department, Hematology Section, University of Bari, Bari and 18Department of Hematology, S. Anna Hospital, Ferrara, Italy
Correspondence:
FRANCESCA R. MAURO - mauro@bce.uniroma1
doi:10.3324/haematol.2019.235705
References
1. Keating MJ, O'Brien S, Albitar M, et al. Early results of a chemoim- munotherapy regimen of fludarabine, cyclophosphamide, and ritux- imab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol. 2005;23(18):4079-4088.
2. Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lym- phocytic leukemia: a randomized, open-label, phase 3 trial. Lancet. 2010;376(9747):1164-1174.
3. Fischer K, Bahlo J, Fink AM, et al. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. Blood. 2016;127(2):208-215.
4. Thompson PA, Tam CS, O'Brien SM, et al. Fludarabine, cyclophos- phamide, and rituximab treatment achieve long-term disease-free
survival in IGHV-mutated chronic lymphocytic leukemia. Blood.
2016;27(3):303-309.
5. RossiD,Terzi-di-BergamoL,DePaoliL,etal.Molecularprediction
of durable remission after first-line fludarabine-cyclophosphamide- rituximab in chronic lymphocytic leukemia. Blood. 2015; 126(16):1921-1924.
6. Wierda W, Kipps T, Mayer J, et al. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocyt- ic leukemia. J Clin Oncol. 2010;28(10):1749-1755.
7. Robak T, Warzocha K, Govind Babu K, et al. Ofatumumab plus flu- darabine and cyclophosphamide in relapsed chronic lymphocytic leukemia: results from the COMPLEMENT 2 trial. Leuk Lymphoma. 2017;58(5):1084-1093.
8. Hillmen P, Robak T, Janssens A, et al. Chlorambucil plus ofatumum- ab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial. Lancet. 2015;385(9980):1873- 1883.
9. Wu Y, Wang Y, Gu Y, et al. Safety and efficacy of ofatumumab in chronic lymphocytic leukemia: a systematic review and meta-analy- sis. Hematology. 2017;22(10):578-584.
10. Wierda WG, Kipps TJ, Dürig J, et al. Chemoimmunotherapy with O- FC in previously untreated patients with chronic lymphocytic leukemia. Blood. 2016;117(24):6450-6458.
11. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagno- sis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updat- ing the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111(12):5446-5456.
12. Rawstron AC, Böttcher S, Letestu R, et al. Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonized approach for flow cytometric residual dis- ease monitoring in CLL. Leukemia. 2013;27(1):142-149.
13. Kater AP, Seymour JF, Hillmen P, et al. Fixed duration of venetoclax- rituximab in relapsed/refractory chronic lymphocytic leukemia erad- icates minimal residual disease and prolongs survival: post-treatment follow-up of the MURANO phase III study. J Clin Oncol. 2019;37(4):269-277.
14. Brown JR, O'Brien S, Kingsley CD, et al. Durable remissions with obinutuzumab-based chemoimmunotherapy: long-term follow-up of the phase 1b GALTON trial in CLL. Blood. 2019;133(9):990-992.
15. Shanafelt TD, Wang XV, Kay NE, Hanson CA, O'Brien S, Barrientos J, et al. Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia. N Engl J Med. 2019;381(5):432-443.
haematologica | 2020; 105(11)